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Previewsare leading to the identification of thera-
peutic targets and the potential reposi-
tioning of existing drugs with good safety
profiles that modulate the genetically-
validated pathways active in patients or
those at risk of the disease (Plenge
et al., 2013). What clues do these new re-
sults offers for therapeutic strategies in
autoimmune disease? As the authors
discuss, targeting the ATPase activity of
MDA5 might not be that useful, notwith-
standing the reasonable position that
pharmacological inhibition of an essential
antiviral defense molecule might not be
safe. Nevertheless, this study and others
indicate that targeting more downstream
autoimmune events as a consequence
of activating variants of MDA5, such as
inhibition of the IL-6 receptor or of
TNF-a or depletion of (antigen-specific, if
possible) effector B and T cells and/or
improving immunosuppressive T regula-
tory cell functions, such as CTLA-4 or
IL-10, might provide safe therapeutic
approaches. There are obviously already
successful drugs in use clinically for
some of these targets (Plenge et al.,2013). Nevertheless, dose and frequency
of administration of the appropriate drug
in humans (results from mice might not
translate) should be determined in rela-
tively small, open-label, statistically-
designed, mechanistic studies or trials to
investigate immunological efficacy before
launching into large and expensive late-
phase trials. The beauty of this new
single-gene model of autoimmune dis-
ease is that it is caused by a single gene
that is also an autoimmune disease gene
in humans and could therefore be useful
to explore therapeutics preclinically. As
discussed recently (Plenge et al., 2013),
knowledge from human genetics and
genomics studies is, and will continue,
transforming medicine.REFERENCES
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T cells are among the most sensitive of cells, but in this issue of Immunity, Honda et al. (2014) demonstrate
that effector T cells must lose their touch within hours to protect the host from immunopathology.In this issue of Immunity, Honda et al.
(2014) use a delayed-type hypersensitivity
(DTH) model to look at how highly sensi-
tive T cells turn off responses at sites of
inflammation. One of the major problems
that prevented prior studies from being
able to address this issue was asyn-
chrony. The DTH model offered a way to
synchronize the response to antigen and
observe it through the intact ear skin
by two-photon microscopy. Honda et al.
(2014) take advantage of the fact that
recruitment of activated T cells into sites
of inflammation is antigen independent.Therefore, when mice are injected with a
strong adjuvant and a mixture of keyhole
limpet hemocyanin (KLH) and ovalbumin
peptide (OVA) subcutaneously and then
challenged by intradermal injection of
KLH in the ear pinnae 7 days later, the
activation of a few KLH-specific cells in
the dermis leads to recruitment of more
KLH- and OVA-specific cells over the
next couple of days (Honda et al., 2014).
The inflammation induced by the T cells
leads to ear swelling, and the OVA-spe-
cific T cells migrate within the inflamed
dermis in search of antigen. IntravenousOVA peptide introduced at this point
rapidly permeates into the inflamed site
and loads onto I-Ab molecules to activate
OVA-specific T cells, leading to arrest of
the T cells within 1 min. Thus, the activa-
tion process can be synchronized and
the kinetics of the effector cell response
to antigen in an inflammatory setting
could be studied in detail.
Honda et al. (2014) first asked whether
the apparent desensitization of the T cells
was due to loss of antigen, other changes
in theAPCs,or achange in theTcells. They
found that antigen was still active byFebruary 20, 2014 ª2014 Elsevier Inc. 169
Figure 1. PD-L1 Is Required for T Cell Desensitization
Fresh effector T cells utilize antigen and adhesion molecules to form a stable synapse in response to few MHC-peptide ligands. Changes in the T cell, including
upregulation of PD-1, coincide with PD-L1-dependent desensitization. PD-L1 may act by binding to PD-1 or CD80 on T cells to attenuate the T cell response.
These antigen-dependent kinapses may allow chemokine production that can recruit fresh T cells into the reaction as long as antigen is present.
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Previewsinjecting a second cohort of OVA-specific
effector cells by adoptive transfer, which
then entered the tissue site, stopped in
contact with tissue APCs, and produced
cytokine. Thus, antigen was still present
and the APCs were fully competent.
This suggested that the T cells were
desensitizing.
T cells have remarkable sensitivity to
antigen, so it was of interest to know
what accounted for this loss of touch.
The expression of T cell receptor re-
mained high and essentially constant
throughout the time course. However,
they found that increased PD-1 expres-
sion on antigen-specific T cells correlated
with a physical dissociation from APCs
and that PD-L1 antibodies could delay
the departure of the T cells and sustain
cytokine production (Honda et al., 2014).
A caveat with use of the PD-L1 antibody
is that PD-L1 also binds to CD80. Honda
et al. (2014) show that PD-L1 is expressed
on both the T cells and APCs, but they
don’t evaluate CD80 expression on the
T cells. This interaction has also been
implicated in inhibition of T cell functions
(Butte et al., 2007). Thus, although PD-1
ligation by PD-L1 is the most likely molec-
ular explanation, the experiments per-
formed do not rule out other edges in
the cosignaling network. Blocking CTLA-
4, another candidate for T cell mobiliza-
tion, had a minor stabilizing effect, but
it did not reach statistical significance.
A challenge in this experiment is that
some CTLA-4 antibodies are agonistic
for motility and might simply replace the
go signal provided by CD80 and CD86170 Immunity 40, February 20, 2014 ª2014 Ewith one delivered by the antibody
(Ruocco et al., 2012). It is clear, however,
that the cosignaling network has a sig-
nificant role in acutely controlling T cell
sensitivity to antigen (Figure 1).
PD-1 is under intense scrutiny as
a potential therapeutic target. PD-1
signaling has differential effects on T cell
responses, with high amounts of PD-1
required to inhibit chemokine production,
intermediate levels to inhibit interferon
production, and low amounts needed
to inhibit proliferation in a model system
(Wei et al., 2013). Although Honda et al.
(2014) did not investigate chemokine
production by the CD4+ effector T cells
in this study, T-cell-derived chemokines
have been shown to be important in
driving immunopathology in other sys-
tems. In an LCMV meningitis model,
CD8+ T cells displayed rapid motility in
the meninges and produced chemokines
that recruit myelomonocytic cells, leading
to fatal seizures because of proximity
to the central nervous system (Kim et al.,
2009). It is possible the T cells are not
fully desensitized, but the transient
‘‘kinapses’’ between the motile T cells
and APCs may lead to production of
chemokines that propagate inflammation.
Honda et al. (2014) conclude that PD-1
overcomes the stop signal, which in turn
sets limits on T cell delivery of cytokine
to a single APC. Results from Fife et al.
(2009) in vivo and Yokosuka et al. (2012)
in vitro concur that PD-1 engagement
overrides stop signals. In contrast, results
from Zinselmeyer et al. (2013) show that
PD-1 interactions in chronic LCMV infec-lsevier Inc.tion contribute to more stable interactions
of antigen-specific T cells with APCs in
the spleen. The control of acute LCMV
infection doesn’t involve stable interac-
tions between effector T cells and in-
fected targets. Chronic LCMV infection,
in contrast, led to substantial T cell decel-
eration and arrest, which was directly
shown to be dependent on PD-1 and
PD-L1 based on blocking antibodies.
The potential of PD-1 and PD-L1 in
enhancing arrest was confirmed in vitro
via freshly isolated LCMV-specific CD8+
T cells, despite the inhibition of early
TCR signaling. The mechanism by which
early TCR signaling is dissociated from
effects on T cell polarity to maintain a sta-
ble inhibitory synapse is not known. As
discussed by Honda et al. (2014), these
early data sets start to expose the huge
regulatory complexity in balancing anti-
gen, adhesion, chemokines, and diverse
cosignaling in vivo.
Honda et al. (2014) analyze a full cycle
of antigen-dependent arrest and resto-
ration of motility at the effector stage
in vivo, demonstrating a faster cycle time
than previously revealed for priming by
Mempel et al. (2004). This relatively short
period of arrest in response to a bolus in-
jection of antigen could even be captured
in a single continuousmovie (8 hr). IFN-g
is produced during the transient arrest
and probably is being concentrated in
immunological synapses targeting partic-
ular APCs although this remains to be
demonstrated in vivo (Huse et al., 2006).
Honda et al. (2014) have taken a bold
step forward in opening the analysis of
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Previewseffector T cell desensitization at the sin-
gle-cell level. Along with single-cell anal-
ysis of other parameters, this study sets
a path to a richer picture of the immune
response that should lead to better design
of vaccines and interventions against
immunopathology.REFERENCES
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CD103+ dendritic cells (DCs) must acquire soluble food antigens from the gut lumen to induce oral tolerance.
In this issue of Immunity, Mazzini et al. (2014), report that CX3CR1
+ macrophages capture such antigen and
transfer it to the DCs by a route involving gap junctions.To maintain tolerance toward proteins
from food, mononuclear phagocytes in
the gut mucosa, including the lamina
propria, must sample antigens from the
intestinal lumen and deliver them to lymph
nodes for presentation to T cells.
The lamina propria of the small intes-
tine in mice contains several populations
of mononuclear phagocytes (Figure 1).
Prominent among those are migratory
dendritic cells (DCs)—marked by the
expression of the integrins CD11c,
CD11b and CD103, and macrophages—
marked by the chemokine receptor
CX3CR1 and F4/80 (Varol et al., 2009).
Intestinal CD103+ DCs are short-lived
cells destined to migrate into the drain-
ing mesentery lymph nodes (LNs). Upon
arriving there they prime or tolerize
T cells, depending on the inflammatory
context (Laffont et al., 2010). Thus
CD103+ DCs are thought to be critical for
maintaining T cell tolerance and for elicit-
ing immune response against gut patho-
gens (Schulz et al., 2009). Themore abun-dant CX3CR1
+macrophages are relatively
long-lived phagocytes that do not nor-
mally migrate to LNs and are not as effi-
cient at presenting antigen (Ag) to T cells.
Their immunological role is debated.
When sampling particulate antigen, DCs
can manage on their own. In response
to Salmonella, for instance, DCs enter the
epithelium, send dedicated dendrites to
phagocytose the bacteria, and then pro-
cess their antigens and carry them to the
draining lymphnodes forpresentation (Far-
ache et al., 2013). In contrast, the DCs are
inefficient samplers of soluble antigens,
although their presentation is essential for
maintaining tolerance toward food anti-
gens. Surprisingly, several studies have
shown that CX3CR1
+macrophages gather
this sort of antigen much more efficiently
than DCs (Schulz et al., 2009; Farache
et al., 2013). A major mechanism the mac-
rophages use is sending dendrites, depen-
dent on CX3CR1 signaling, to the gut
lumen. Antigen may also directly flow into
the lamina propria through goblet cells tobe collected there by the macrophages
(McDole et al., 2012).
The complementing specialties of the
two cell populations, one in uptake of
antigen and the other in its presentation,
raises an interesting possibility—could
CX3CR1
+ macrophages and CD103+ DCs
be collaborating? Could macrophages be
in charge of capturing the Ag and deliv-
ering it to DCs that would in turn carry it
to the lymph node for presentation?
In an elaborate study, the group led by
Maria Rescigno now shows that this is
indeed the case (Mazzini et al., 2014).
Their research follows the extent, mecha-
nism, and immunological consequences
of antigen transfer betweenmacrophages
and DCs in the intestinal lamina propria of
the mouse small intestine.
The study started by verifying, by using
histology and flow cytometry, that solu-
ble ovalbumin was taken up efficiently
by CX3CR1
+ macrophages, but not by
CD103+ DCs. Interestingly, uptake by
macrophages was largely limited to theFebruary 20, 2014 ª2014 Elsevier Inc. 171
